Current Topics in Histocompatibility & Transplantation



Similar documents
Current Topics in Histocompatibility & Transplantation

Search Coordinator Certificate

NATCO Introductory Education Course Objectives

THE INFLUENCE OF TISSUE (IN)COMPATIBILITY IN UMBILICAL CORD BLOOD TRANSPLANTATION

Human Leukocyte Antigens - HLA

The Danish Bone Marrow Donor Registry DBMDR

Helping you find the one match.. Guide for Unrelated Stem Cell Transplant Patients OneMatch Stem Cell and Marrow Network BLOOD.

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION

Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

Program Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD

Summary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status

Stem Cell Quick Guide: Stem Cell Basics

New Zealand Bone Marrow Donor Registry

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

Public Cord Blood Banking at the National Cord Blood Program (NCBP)

On April 4, a group of physicians at the 37th annual

HISTO TYPE SSP Immunogenetic Diagnostics. Robust and fast - validated Taq Polymerase included

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

Stem Cells and Hope for Patients

Ph.D. in Molecular Medicine

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

Kidney and Pancreas Transplant Evaluation Clinics and Committee: Inpatient Nephrology Transplant Consult Service

STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research

Ocular Surface Diseases Course 2016 MIAMI,FLORIDA. Bascom Palmer Eye Institute. Sponsored by the University of Miami Miller School of Medicine

Public Cord Blood Tissue Bank Committee on Health Care Services and Representative Peaden

How to select a donor and product for allogeneic HCT

6th Annual. Children s Medical Center Transfusion & Laboratory Medicine Conference February 13-15, 2013

5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

UMBILICAL CORD BLOOD COLLECTION

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

OVERVIEW OF CURRENT STATUS OF STEM CELL TRANSPLANTATION IN VIETNAM

Transplant Quality Institute

CORD BLOOD BANKING FAQ

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points

How To Treat Leukaemia With Cord Blood Stem Cell

Stem cells and motor neurone disease

The TV Series. INFORMATION TELEVISION NETWORK

CONSENT FORM. Cord Blood Banking for Transplantation

Department of Veterans Affairs VHA DIRECTIVE Veterans Health Administration Washington, DC July 9, 2012

SEARCHING FOR A BONE MARROW DONOR

Research Associate BLOOD AND MARROW TRANSPLANT FACULTY POSITIONS HEMATOLOGY/ONCOLOGY FACULTY POSITIONS IN PRECISION CANCER MEDICINE

YOU RE A POTENTIAL MATCH

Using Cost Effectiveness Analysis to Determine Inventory Size for a National Umbilical Cord Blood Bank

What is a Stem Cell Transplantation?

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several

How To Support Umbilical Cord Blood Stem Cell Research

Blood-Forming Stem Cell Transplants

Key Staff Members EXECUTIVE TEAM Nancy Price Mendenhall, MD Medical Director Stuart Klein, MHA Executive Director Zuofeng Li, DSc Physics Director

CordBank Limited, which supplies processing and services with respect to cord blood. CordBank is referred to in this contract as CordBank or we ;

Guidance For Research Involving Human Embryonic Stem Cells, Germ Cells, And Cells Obtained From Cord Blood

The Treatment of Leukemia

4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

Clinical Trials: Questions and Answers

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa

Multiple Myeloma. This reference summary will help you understand multiple myeloma and its treatment options.

Corporate Medical Policy

Q: Why is there a need for people to join the Be The Match Registry?

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Presents Live from New York: It s Pediatric Hematology/Oncology Updates

A Genetic Analysis of Rheumatoid Arthritis

ATTACHMENT I TO APPENDIX B OF UNOS BYLAWS

Infection Prevention WEBINAR SERIES

SAVE A LIFE... BY GIVING LIFE!

OpenMedicine Foundation (OMF)

Newborn Blood Banking, Inc. P.O. Box Tampa, Florida Phone (813)

»medical programs and services. transfusion medicine fellowship program

TOMORROW S HEALTHCARE STARTS HERE

Where World-Class Expertise and Genuine Compassion Come Together. AT THE FOREFRONT OF TRANSPLANT CARE Kidney Combined Kidney-Pancreas Pancreas Islets

NORTHWEST TRANSFUSION SYMPOSIUM. Final Program. Tacoma, Washington 9/12/2015

Reference: NHS England B04/P/a

AssureImmune. Cord Blood: For Something That Precious, Bank with the Best. Important Facts for When You re Expecting. AssureImmune.

INTRODUCTION. Chapter One

STEM CELL THERAPEUTIC OUTCOMES DATABASE

Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris

Briefing on the second reading of the Human Fertilisation and Embryology Bill, Monday 19 November 2007.

5 Frequently Asked Questions About Adult Stem Cell Research

Public Law th Congress

PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES.

Transcription:

Current Topics in Histocompatibility & Transplantation A Unique Continuing Education Opportunity 2007 Teleconference Series Sponsored by Sandra Rosen-Bronson, Ph.D., D.(ABHI) Georgetown University Washington, DC An ABHI Approved Continuing Education Program

2 Current Topics in Histocompatibility and Transplantation for Technologists This series of twenty interactive lectures, moderated by Dr. Sandra Rosen-Bronson, will reach scores of individuals through real-time, ninety minute in-depth audio conferences involving organizations and people from around the world. Without ever leaving your laboratory or office, you can listen to expert scientists and key decision makers thousands of miles away. You can ask questions and get immediate answers as well as listen to other participants questions and discussions. This convenient and cost-effective educational tool will allow you to keep current in the field of histocompatibility testing and transplantation. Each participant will earn ABHI Continuing Education Credit (CEC) equal to 1.5 contact hours or 0.225 CEC per lecture. All teleconferences are scheduled to start at 1:00 P.M. (Eastern Time) and last approximately ninety minutes. In addition, lecture outlines and slides will be provided to each participating site. Any Questions? How Does a Teleconference Work? Three to five days before each lecture, a teleconference packet will be mailed to your site coordinator containing the lecture slides, outline, and dial-in instructions. U.S. participants will receive a toll-free telephone number. International participants may incur additional telephone charges. On the day of the lecture and at the scheduled time, your site will call the telephone number provided in your lecture packet. Once all conference sites have dialed in, participants will follow the slide show with the lecturer. You will have an opportunity to participate in a question and answer discussion session at both the midpoint and at the completion of the lecture. What Equipment Do We Need On Site? You will need a 35 mm slide or LCD projector with a screen and a speakerphone. You may also want to obtain a quality teleconference system for maxium audio reception and clarity. Your organization s telecommunications department may have one available. Alternatively, units can be purchased from companies such as HELLO Direct (800-444-3556, www.hello-direct.com) or rented from A.T. Products, Inc. (800-848-2205). How Do We Register? Complete the teleconference registration form. Fax the form to: (202) 687-1244. Send the original registration form and a check made payable to Georgetown University to: U.S. Mail: Sandra Rosen-Bronson Box 571438 Georgetown University 3900 Reservoir Road NW Washington DC 20057-1438 Overnight Courier: Sandra Rosen-Bronson Preclinical Science Bldg, Room LE8H Georgetown University 3900 Reservoir Road NW Washington DC 20007 (202) 784-2909 In order to assure your registration, it is important to write our complete and exact address as listed above. Cancellation Policy: Cancellations which occur 21 days or more prior to the date of the first lecture for which your site has registered are fully refundable less a nonrefundable deposit of $50. For cancellations which occur from 21 to 14 days prior, 50% of the lecture series fee will be forfeited. No refunds are possible after 14 days prior to the starting date. All cancellation requests must be submitted in writing. Further Questions: If you have questions about the registration process or need a registration form, please contact Dr. Rosen-Bronson or Andrey Evseev at: Tel: (202) 784-5518 or (202) 687-8924 Fax: (202) 687-1244 Email: bronson@gunet.georgetown.edu

3 2007 Teleconference Schedule All dates are Tuesdays and all lectures begin at 1:00 P.M. (Eastern Time) March 27, 2007 Is Hematopoietic Stem Cell Donation Right for Me? Judith Lawrence, R.N. Donor Stem Cell Coordinator, Georgetown University Hospital, Washington, DC and David Means, M.P.H. Workup Supervisor, C.W. Bill Young Marrow Donor Program, Rockville, MD Participants will learn how to join the NMDP donor registry and will gain an understanding of the roles of the donor recruitment center and the stem cell collection facility. They will hear about the steps involved once an individual is selected to be a stem cell donor for a patient and will hear about the experience first hand from a donor. April 3, 2007 Getting to Know the T Cell and Its Receptor Carolyn Hurley, Ph.D., D.(ABHI) Georgetown University and the C.W. Bill Young Marrow Donor Program, Washington, DC This basic lecture will provide participants with an understanding of the genes that encode T cell receptors along with information about their molecular structure. Participants will learn how T cell receptors function and their role in the immune response. April 17, 2007 Hematopoietic Stem Cell Transplantation from the Patient s Perspective Jennifer Wilder, R.N., B.S.N., O.N.C. Hematopoietic Stem Cell Transplant Program, National Institutes of Health, Bethesda, MD Stem cell transplantation can be a life saving and life-changing experience, but from diagnosis to recovery, patients facing transplant can have a long road to travel. Jennifer Wilder is an experienced transplant nurse as well as donor search coordinator and has traveled this road with many patients. Conference participants will gain an understanding of stem cell transplant clinical protocols and the transplant experience from the patient s perspective. May 1, 2007 Solid Phase Antibody Assays: Their Power and Their Pitfalls Karen Nelson, Ph.D., D.(ABHI) Puget Sound Blood Center, Immunogenetics Laboratory, Seattle, WA The number of manufactures offering some form of solid phase assay for HLA antibody analysis continues to grow. As more laboratories incorporate such assays into their routine test repertoire, there is also a growing need for HLA laboratories to understand the strengths and weaknesses of the assays. This lecture will provide an overview of the solid phase assays available today and will discuss problem issues along with critical questions such as how to interpret and use assay results in the transplant setting. May 15, 2007 Therapeutic Protocols: Challenges and Resolutions Benita Book, M.S. Transplant Immunology Laboratory, Indiana University Department of Surgery, Indianapolis, IN and Nancy Higgins, M.T., C.H.S. Transplant Immunology Laboratory, Methodist Hospital, Indianapolis, IN This lecture will identify drugs that are known to interfere with histocompatibility testing and will describe methods for eliminating interference. This conference will include examples of patient cases where drug interference was encountered and the speakers will describe the steps taken to resolve the problem.

4 May 22, 2007 Immunogenetics for Beginners Sandra Rosen-Bronson, Ph.D.,D.(ABHI) Histocompatibility Laboratory, Georgetown University Hospital, Washington, DC This basic lecture will provide an overview of the evolving field of immunogenetics. Participants will learn about current research tools designed to identify the genes of the immune system along with genes that interact with the immune system and contribute to disease susceptibility or prognosis. June 5, 2007 Pillow Talk: Peptide and MHC Interactions David Eckels, Ph.D., D.(ABHI) Histocompatibility and Immunogenetics Laboratory, University of Utah School of Medicine, Salt Lake City, UT This basic lecture will discuss the organization and diversity of MHC and will discuss how the structure of HLA molecules is uniquely suited to their peptide binding function. Participants will learn how the HLA polymorphism affected peptide binding as well as how HLA/peptide complexes are recognized by T cell receptors. June 19, 2007 Unique and Challenging Cases in the HLA Typing Laboratory Neng Yu, M.D., D.(ABHI) American Red Cross New-England Region, Dedham, MA The HLA laboratory can often encounter unusual and confusing typing results with a variety of explanations. Participants in this conference will hear about a particularly interesting case of disputed maternity and will learn about the laboratory investigation performed to resolve this mysterious case. June 26, 2007 Organ Donation Through the Eyes of the OPO Andrea Tighe, R.N., C.P.T.C. Procurement Manager, LifeSource, St Paul, MN Organ donation, the ultimate gift of life, requires an extensive team of courageous, sensitive, and highly skilled individuals. Participants in this conference will gain an understanding of the donation process from the initial identification of a potential donor through final allocation of the donor s organs. July 17, 2007 T Cell Directed Therapies John O Shea, M.D. Scientific Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD Agents that interfere with T cell function are therapeutic mainstays for a variety of autoimmune diseases and immunosuppression protocols. Participants will learn about T cell specific agents now in use as well as those currently being investigated.

5 July 24, 2007 Small Bowel Transplantation Stuart Kaufman, M.D. Medical Director, Intestinal Transplantation, Georgetown University Hospital and Children s National Medical Center, Washington, DC The number of small bowl transplants has grown to approximately one hundred per year. While progress in organ preservation, surgical technique, immunosuppression, and postoperative management has helped to improve outcomes, the procedure is still associated with significant mortality and morbidity including infection, rejection, and graft-versus-host disease. Participants will not only learn about small bowel transplantation, but will also gain a greater understanding of the need for a unique partnership between the clinical laboratory and the transplant team. July 31, 2007 Cord Blood Transplantation Mary Halet, B.S., C.H.T.C. Manager of Cord Blood Program, National Marrow Donor Program, Minneapolis, MN Over the past several years, the use of cord blood as a source of hematopoietic stem cells for transplantation has continued to increase. With improved collection techniques along with the use of dual cord units, cord blood stem cells are a viable option for a growing number of adult transplant patients. This lecture will provide an overview of current practice and investigation in the field of cord blood transplantation. August 7, 2007 Neuroimmunology Jonathan Godbout, Ph.D. Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, OH Neuroimmunology is a growing area of research that studies all aspects of the interactions between the immune system and the nervous system. Participants will learn about the physiological functioning of the neuroimmune system in health and disease and will hear how malfunctions of this system are involved in disorders such as autoimmune disease, hypersensitivities, and immune deficiency. August 21, 2007 DNA Sequencing for Beginners Denise Heaney, Ph.D. Histocompatibility and Immunogenetics Laboratory, Emory University Hospital, Atlanta, GA This basic lecture will provide participants with an overview of the principles and the molecular biology methods employed for DNA sequencing. Manual along with automated methods will be described and troubleshooting issues will be discussed. August 28, 2007 The Effects of HLA and KIR Genes on Disease Susceptibility and Outcome Mary Carrington, Ph.D. Human Genetics Laboratory, National Cancer Institute at Frederick, Frederick, MD Dr. Carrington will discuss her research on the effects of HLA and KIR genes in several types of diseases including infectious diseases, autoimmune diseases, and cancer. Participants will learn about studies that demonstrate that KIR and HLA genes can interact synergistically to affect resistance or susceptibility to disease.

6 September 18, 2007 Update 2007: The Future of Kidney Allocation in the U.S. M. Sue Leffell, Ph.D., D.(ABHI) Immunogenetics Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD The OPTN/ UNOS Board s special review group, the Kidney Allocation Review Subcommittee (KARS), continues to work toward the development of a new allocation system based on a calculated net lifetime survival benefit (NLSB). Dr. Leffell, as a member of the KARS and the current chair of the OPTN/UNOS Histocompatibility Committee, has been intimately involved with this process and will provide participants with an update on this critical and controversial initiative. September 25, 2007 The Ethics of Stem Cell Research Kevin FitzGerald, S.J., Ph.D. The David Lauler Chair in Catholic Health Care Ethics, Center for Clinical Bioethics and Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC This conference will include a discussion of the ethical questions surrounding current genetic research and the ongoing stem cell discussion in our society. Fr. FitzGerald holds doctorates in both molecular genetics and bioethics. He has published extensively on stem cell research, human cloning, and health care ethics. As a research scientist as well as a Christian ethicist, Fr. FitzGerald brings a unique perspective to this controversial topic. October 23, 2007 The Role of KIR and KIR Ligands in HCS Transplant Outcome and Disease Relapse Katharine Hsu, M.D. Bone Marrow Transplantation, Memorial Sloan Kettering Cancer Center, New York, NY Inhibitory killer immunoglobulin (Ig)-like receptors (KIRs) recognize HLA-C and -B epitopes on target cells and are known to be involved in regulating natural killer (NK) cell activity. This conference will provide an update on current research into the role of KIR in HSC transplantation. November 13, 2007 Transplanting the Highly Sensitized Patient Kathryn Tinckam, M.D., M.MSc., F.R.C.P.C. Renal Division and Tissue Typing Laboratory, Brigham and Women s Hospital, Boston, MA This conference will discuss useful strategies for successfully transplanting patient s with high levels of HLA antibody. Pre-transplant assays as well as protocols for post-transplant alloimmune monitoring will be covered. November 20, 2007 HLA Matching for Hematopoietic Stem Cell Transplantation Stephanie Lee, M.D., M.P.H. Fred Hutchinson Cancer Research Center, Seattle, WA Fewer than fifty percent of the patients who need a hematopoietic stem cell transplant are able to identify an HLA-A, -B, -C, -DRB1 allele matched unrelated donor. Nevertheless, an increasing number of patients are being successfully transplanted with a mismatched donor. This conference will review current research concerning the clinical relevance of various HLA mismatches.

7 Current Topics in Histocompatibility & Transplantation A Unique Continuing Education Opportunity 2007 Georgetown University, Washington, DC